<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787473</url>
  </required_header>
  <id_info>
    <org_study_id>HZCH-2016-10</org_study_id>
    <nct_id>NCT02787473</nct_id>
  </id_info>
  <brief_title>A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and toxicity of patients with inoperable squamous cell lung cancer
      treated with pemetrexed plus cisplatin with concurrent radiation therapy followed by
      docetaxel consolidation. An exploratory biomarker analysis in blood and tumor samples is also
      planned.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The short-term quality of life (QOL) assessed using FACT-E score</measure>
    <time_frame>4 months</time_frame>
    <description>FACT-E score at the 4 months after docetaxel consolidation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CTCAE grade 2 or higher radiation pneumonitis</measure>
    <time_frame>1 years</time_frame>
    <description>The investigators will assess the rate of symptomatic radiation pneumonitis in patients who received the radiation therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Squamous Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pemetrexed+carboplatin/cisplatin+radiation therapy-&gt;docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received pemetrexed 500mg/m2 days 1,29+cisplatin 25 mg/m2 days 1-3,29-31 + Radiation 6000 cGy (200 cGy/day). Patients with complete response(CR), partial response(PR) or stable disease(SD) with manageable toxicity received docetaxel 60 mg/m2 days 57,78.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles</description>
    <arm_group_label>pemetrexed+carboplatin/cisplatin+radiation therapy-&gt;docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles</description>
    <arm_group_label>pemetrexed+carboplatin/cisplatin+radiation therapy-&gt;docetaxel</arm_group_label>
    <other_name>platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>thoracic radiation therapy</intervention_name>
    <description>Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin</description>
    <arm_group_label>pemetrexed+carboplatin/cisplatin+radiation therapy-&gt;docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles</description>
    <arm_group_label>pemetrexed+carboplatin/cisplatin+radiation therapy-&gt;docetaxel</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed stage IIIA/ IIIB squamous cell lung cancer;

          -  All sites of disease must be amenable to definitive radiotherapy;

          -  Age 18 years to 75 years;

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2;

          -  Forced expiratory volume in 1 second(FEV1)&gt; 0.75L;

          -  No previous chest radiotherapy, immunotherapy or biotherapy;

          -  Adequate bone marrow, liver and renal function, as specified below: Absolute
             Neutrophil Count (ANC) ≥ 1.5 x 109/L; Hemoglobin ≥ 8 g/dL; Platelets ≥ 100 x 109/L;
             Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) ; Aspartate
             transaminase(AST) and alanine Transaminase(ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if liver
             metastases are present; Serum creatinine ≤ 1.5 x upper limit of normal or creatinine
             clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.

          -  For women of child-bearing potential, negative pregnancy test within 14 days prior to
             starting treatment

          -  Men and women of childbearing age must be willing to use effective contraception while
             on treatment and for at least 3 months thereafter;

          -  Patients and their family signed the informed consents;

        Exclusion Criteria:

          -  Active infection;

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias);

          -  Malnutrition (loss of ≥ 20% of the original body weight);

          -  Performance status: 3-4;

          -  Sensor or motor neuropathy &gt; grade I;

          -  Second primary malignancy, except for non-melanoma skin cancer;

          -  Psychiatric illness or social situation that would preclude study compliance;

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shenglin Ma, MD</last_name>
    <phone>0571-56007908</phone>
    <phone_ext>086</phone_ext>
    <email>mashenglin@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirong Zhang, Dr.</last_name>
      <phone>086057156007650</phone>
      <email>shirley4444@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous cell lung cancer</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Radiosensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

